Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX)
CAPS Rating:
The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.
The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
Recs
Their Hep C drug has the potential to take this company to stardom, however, if the drug fails expect the company to crater. Still, this isn't a one trick pony as they also have tests going in RA, CF, HIV, cancer and pain. So, it's a diversified company that still has a lot riding on Hep C.